EIKN — Eikon Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $534.44m
- $198.47m
Annual cashflow statement for Eikon Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -242 | -244 | -324 |
| Depreciation | |||
| Non-Cash Items | 29.7 | 13.4 | 39 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 9.98 | 80.7 | 77.8 |
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Change in Other Liabilities | |||
| Cash from Operating Activities | -191 | -135 | -189 |
| Capital Expenditures | -28.5 | -84.8 | -46.7 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | 165 | 236 | -135 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | 137 | 151 | -181 |
| Net Issuance / Retirement of Stock | |||
| Cash from Financing Activities | 106 | 0.244 | 352 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 51.9 | 16.8 | -17.8 |